Behavioral activation therapy for depression and anxiety in cancer patients: A case series study

Takatoshi Hirayama, Yuko Ogawa, Yuko Yanai, Shinichi Suzuki, Ken Shimizu

Research output: Contribution to journalArticle

Abstract

Background: Behavioral activation therapy (BAT) directly addresses activities that individuals value most highly, and may be easily applicable to cancer patients. However, there is no established evidence of the use of BAT in this population. In this study, we examined the possibility of a BAT program for depression and anxiety in cancer patients. Case presentation: We retrospectively reviewed the medical records of cancer patients with each of the following characteristics: 1) were outpatients or inpatients visiting the psycho-oncology division of the National Cancer Center Hospital in Japan; 2) met criteria for Major Depressive Disorder or Adjustment Disorders; and 3) participated in a BAT program. The primary outcome was the program completion percentage. Secondary outcomes were self-reported depression severity (Patient Health Questionnaire-9 (PHQ-9) score), anxiety disorder status (Generalized Anxiety Disorder-7 (GAD-7) score), and clinical improvement (Clinical Global Impression-Improvement (CGI-I) score) after the program. We analyzed both depression and anxiety by the matched paired t-test. Ten patients participated in the program, and nine completed it. One dropped out due to cognitive impairment secondary to brain metastasis. Both the PHQ-9 scores (pre: 14.4 (SD, 6.1); post: 5.1 (SD, 5.8)) and the GAD-7 scores (pre: 11.9 (SD, 4.9); post: 4.7 (SD, 5.5)) significantly improved after the program (PHQ-9: P = 0.0014; GAD-7: P = 0.0004). CGI-I scores ranged from 1 to 3, and all subjects except the patient who dropped out improved clinically. Among the ten patients, three distinctive cases could be observed as follows. Case 1; a 45-year-old housewife with breast cancer who did not agree to take antidepressants because of concerns about the side effects achieved remission without antidepressants and began to live an active life. Case 4; a 66-year-old housewife was so shocked after endometrial cancer diagnosis that she was absent-minded and her compliance with the assigned homework was poor, therefore, her depression did not improve much. Case 9; a 62-year-old man with laryngeal cancer who had recurrent anxiety. Increased business activity, on which he put great value, gradually allowed him to be able to live his life actively without concerns. Conclusions: This study suggests that BAT would be effective for the depression and anxiety of cancer patients.

Original languageEnglish
Article number9
JournalBioPsychoSocial Medicine
Volume13
Issue number1
DOIs
Publication statusPublished - 2019 Apr 29

Fingerprint

Anxiety
Depression
Neoplasms
Anxiety Disorders
Therapeutics
Antidepressive Agents
Health
Adjustment Disorders
Cancer Care Facilities
Laryngeal Neoplasms
Major Depressive Disorder
Endometrial Neoplasms
Medical Records
Inpatients
Japan
Outpatients
Breast Neoplasms
Neoplasm Metastasis
Brain
Population

Keywords

  • Adjustment disorders
  • Anxiety
  • Behavioral activation therapy
  • Cancer
  • Depression
  • Psychotherapy

ASJC Scopus subject areas

  • Social Psychology
  • Psychology(all)
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Behavioral activation therapy for depression and anxiety in cancer patients : A case series study. / Hirayama, Takatoshi; Ogawa, Yuko; Yanai, Yuko; Suzuki, Shinichi; Shimizu, Ken.

In: BioPsychoSocial Medicine, Vol. 13, No. 1, 9, 29.04.2019.

Research output: Contribution to journalArticle

Hirayama, Takatoshi ; Ogawa, Yuko ; Yanai, Yuko ; Suzuki, Shinichi ; Shimizu, Ken. / Behavioral activation therapy for depression and anxiety in cancer patients : A case series study. In: BioPsychoSocial Medicine. 2019 ; Vol. 13, No. 1.
@article{9a4c9b7c64e14e21a29f4d3f772de63b,
title = "Behavioral activation therapy for depression and anxiety in cancer patients: A case series study",
abstract = "Background: Behavioral activation therapy (BAT) directly addresses activities that individuals value most highly, and may be easily applicable to cancer patients. However, there is no established evidence of the use of BAT in this population. In this study, we examined the possibility of a BAT program for depression and anxiety in cancer patients. Case presentation: We retrospectively reviewed the medical records of cancer patients with each of the following characteristics: 1) were outpatients or inpatients visiting the psycho-oncology division of the National Cancer Center Hospital in Japan; 2) met criteria for Major Depressive Disorder or Adjustment Disorders; and 3) participated in a BAT program. The primary outcome was the program completion percentage. Secondary outcomes were self-reported depression severity (Patient Health Questionnaire-9 (PHQ-9) score), anxiety disorder status (Generalized Anxiety Disorder-7 (GAD-7) score), and clinical improvement (Clinical Global Impression-Improvement (CGI-I) score) after the program. We analyzed both depression and anxiety by the matched paired t-test. Ten patients participated in the program, and nine completed it. One dropped out due to cognitive impairment secondary to brain metastasis. Both the PHQ-9 scores (pre: 14.4 (SD, 6.1); post: 5.1 (SD, 5.8)) and the GAD-7 scores (pre: 11.9 (SD, 4.9); post: 4.7 (SD, 5.5)) significantly improved after the program (PHQ-9: P = 0.0014; GAD-7: P = 0.0004). CGI-I scores ranged from 1 to 3, and all subjects except the patient who dropped out improved clinically. Among the ten patients, three distinctive cases could be observed as follows. Case 1; a 45-year-old housewife with breast cancer who did not agree to take antidepressants because of concerns about the side effects achieved remission without antidepressants and began to live an active life. Case 4; a 66-year-old housewife was so shocked after endometrial cancer diagnosis that she was absent-minded and her compliance with the assigned homework was poor, therefore, her depression did not improve much. Case 9; a 62-year-old man with laryngeal cancer who had recurrent anxiety. Increased business activity, on which he put great value, gradually allowed him to be able to live his life actively without concerns. Conclusions: This study suggests that BAT would be effective for the depression and anxiety of cancer patients.",
keywords = "Adjustment disorders, Anxiety, Behavioral activation therapy, Cancer, Depression, Psychotherapy",
author = "Takatoshi Hirayama and Yuko Ogawa and Yuko Yanai and Shinichi Suzuki and Ken Shimizu",
year = "2019",
month = "4",
day = "29",
doi = "10.1186/s13030-019-0151-6",
language = "English",
volume = "13",
journal = "BioPsychoSocial Medicine",
issn = "1751-0759",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Behavioral activation therapy for depression and anxiety in cancer patients

T2 - A case series study

AU - Hirayama, Takatoshi

AU - Ogawa, Yuko

AU - Yanai, Yuko

AU - Suzuki, Shinichi

AU - Shimizu, Ken

PY - 2019/4/29

Y1 - 2019/4/29

N2 - Background: Behavioral activation therapy (BAT) directly addresses activities that individuals value most highly, and may be easily applicable to cancer patients. However, there is no established evidence of the use of BAT in this population. In this study, we examined the possibility of a BAT program for depression and anxiety in cancer patients. Case presentation: We retrospectively reviewed the medical records of cancer patients with each of the following characteristics: 1) were outpatients or inpatients visiting the psycho-oncology division of the National Cancer Center Hospital in Japan; 2) met criteria for Major Depressive Disorder or Adjustment Disorders; and 3) participated in a BAT program. The primary outcome was the program completion percentage. Secondary outcomes were self-reported depression severity (Patient Health Questionnaire-9 (PHQ-9) score), anxiety disorder status (Generalized Anxiety Disorder-7 (GAD-7) score), and clinical improvement (Clinical Global Impression-Improvement (CGI-I) score) after the program. We analyzed both depression and anxiety by the matched paired t-test. Ten patients participated in the program, and nine completed it. One dropped out due to cognitive impairment secondary to brain metastasis. Both the PHQ-9 scores (pre: 14.4 (SD, 6.1); post: 5.1 (SD, 5.8)) and the GAD-7 scores (pre: 11.9 (SD, 4.9); post: 4.7 (SD, 5.5)) significantly improved after the program (PHQ-9: P = 0.0014; GAD-7: P = 0.0004). CGI-I scores ranged from 1 to 3, and all subjects except the patient who dropped out improved clinically. Among the ten patients, three distinctive cases could be observed as follows. Case 1; a 45-year-old housewife with breast cancer who did not agree to take antidepressants because of concerns about the side effects achieved remission without antidepressants and began to live an active life. Case 4; a 66-year-old housewife was so shocked after endometrial cancer diagnosis that she was absent-minded and her compliance with the assigned homework was poor, therefore, her depression did not improve much. Case 9; a 62-year-old man with laryngeal cancer who had recurrent anxiety. Increased business activity, on which he put great value, gradually allowed him to be able to live his life actively without concerns. Conclusions: This study suggests that BAT would be effective for the depression and anxiety of cancer patients.

AB - Background: Behavioral activation therapy (BAT) directly addresses activities that individuals value most highly, and may be easily applicable to cancer patients. However, there is no established evidence of the use of BAT in this population. In this study, we examined the possibility of a BAT program for depression and anxiety in cancer patients. Case presentation: We retrospectively reviewed the medical records of cancer patients with each of the following characteristics: 1) were outpatients or inpatients visiting the psycho-oncology division of the National Cancer Center Hospital in Japan; 2) met criteria for Major Depressive Disorder or Adjustment Disorders; and 3) participated in a BAT program. The primary outcome was the program completion percentage. Secondary outcomes were self-reported depression severity (Patient Health Questionnaire-9 (PHQ-9) score), anxiety disorder status (Generalized Anxiety Disorder-7 (GAD-7) score), and clinical improvement (Clinical Global Impression-Improvement (CGI-I) score) after the program. We analyzed both depression and anxiety by the matched paired t-test. Ten patients participated in the program, and nine completed it. One dropped out due to cognitive impairment secondary to brain metastasis. Both the PHQ-9 scores (pre: 14.4 (SD, 6.1); post: 5.1 (SD, 5.8)) and the GAD-7 scores (pre: 11.9 (SD, 4.9); post: 4.7 (SD, 5.5)) significantly improved after the program (PHQ-9: P = 0.0014; GAD-7: P = 0.0004). CGI-I scores ranged from 1 to 3, and all subjects except the patient who dropped out improved clinically. Among the ten patients, three distinctive cases could be observed as follows. Case 1; a 45-year-old housewife with breast cancer who did not agree to take antidepressants because of concerns about the side effects achieved remission without antidepressants and began to live an active life. Case 4; a 66-year-old housewife was so shocked after endometrial cancer diagnosis that she was absent-minded and her compliance with the assigned homework was poor, therefore, her depression did not improve much. Case 9; a 62-year-old man with laryngeal cancer who had recurrent anxiety. Increased business activity, on which he put great value, gradually allowed him to be able to live his life actively without concerns. Conclusions: This study suggests that BAT would be effective for the depression and anxiety of cancer patients.

KW - Adjustment disorders

KW - Anxiety

KW - Behavioral activation therapy

KW - Cancer

KW - Depression

KW - Psychotherapy

UR - http://www.scopus.com/inward/record.url?scp=85065038312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065038312&partnerID=8YFLogxK

U2 - 10.1186/s13030-019-0151-6

DO - 10.1186/s13030-019-0151-6

M3 - Article

AN - SCOPUS:85065038312

VL - 13

JO - BioPsychoSocial Medicine

JF - BioPsychoSocial Medicine

SN - 1751-0759

IS - 1

M1 - 9

ER -